Literature DB >> 20880929

Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients.

Marlies Noordzij1, Ellen M Cranenburg, Lyda F Engelsman, Marc M Hermans, Elisabeth W Boeschoten, Vincent M Brandenburg, Willem Jan W Bos, Jeroen P Kooman, Friedo W Dekker, Markus Ketteler, Leon J Schurgers, Raymond T Krediet, Johanna C Korevaar.   

Abstract

BACKGROUND: Previous studies have shown that simple imaging methods may be useful for detection of vascular calcifications in dialysis patients. Based on annual, plain chest X-rays during follow-up on dialysis, we studied the associations of mineral metabolism with the presence and progression of aortic calcification. In addition, we assessed the impact of aortic calcification on mortality.
METHODS: Three hundred and eighty-four patients who started haemodialysis or peritoneal dialysis between 1997 and 2007 were included (age 61 ± 15 years, 64% male, 61% haemodialysis). Annual chest X-rays were screened for calcification in the aortic arch, and patients were categorized as having no, moderate or severe calcification. Progression was defined as an increase in calcification category during follow-up on dialysis.
RESULTS: At baseline, 96 (25%) patients had severe, 205 (53%) patients had moderate and 83 (22%) patients had no aortic calcification. For 237 of the 288 patients with no or moderate calcifications at baseline, X-rays were available for follow-up. During follow-up (mean 2.3 years), aortic calcification progressed in 71 patients (30%). We found that baseline plasma calcium > 9.5 mg/dL and iPTH > 300 pg/mL were associated with progression [odds ratios of 3.1, 95% confidence interval (1.2-8.2) and 4.4 (1.4-14.1), respectively]. Progression of aortic calcification was significantly associated with increased risk of all-cause mortality (hazard ratio: 1.9; 95% CI: 1.2-3.1) and cardiovascular mortality (hazard ratio: 2.7; 95% CI: 1.3-5.6).
CONCLUSIONS: Aortic calcification progressed in almost a third of the patients during dialysis. Hypercalcaemia and hyperparathyroidism were associated with an increased risk of progression. Progression of aortic calcification was significantly related to an increased mortality risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880929     DOI: 10.1093/ndt/gfq582

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  56 in total

1.  Persistently low intact parathyroid hormone levels predict a progression of aortic arch calcification in incident hemodialysis patients.

Authors:  Harin Rhee; Sang Heon Song; Ihm Soo Kwak; Soo Bong Lee; Dong Won Lee; Eun Young Seong; Il Young Kim
Journal:  Clin Exp Nephrol       Date:  2012-01-05       Impact factor: 2.801

2.  Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.

Authors:  Joan Perelló; Miquel D Ferrer; Maria Del Mar Pérez; Nadine Kaesler; Vincent M Brandenburg; Geert J Behets; Patrick C D'Haese; Rekha Garg; Bernat Isern; Alex Gold; Myles Wolf; Carolina Salcedo
Journal:  Br J Pharmacol       Date:  2020-08-23       Impact factor: 8.739

3.  Baseline FGF23 is Associated with Cardiovascular Outcome in Incident PD Patients.

Authors:  Hyo Jin Kim; Miseon Park; Hayne Cho Park; Jong Cheol Jeong; Dong Ki Kim; Kwon Wook Joo; Young-Hwan Hwang; Jaeseok Yang; Curie Ahn; Kook-Hwan Oh
Journal:  Perit Dial Int       Date:  2014-09-02       Impact factor: 1.756

4.  Risk Factors for the Development and Progression of Thoracic Aorta Calcification: The Multi-Ethnic Study of Atherosclerosis.

Authors:  George Youssef; Mengye Guo; Robyn L McClelland; David M Shavelle; Khurram Nasir; Juan Rivera; J Jeffrey Carr; Nathan D Wong; Matthew J Budoff
Journal:  Acad Radiol       Date:  2015-09-26       Impact factor: 3.173

5.  Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.

Authors:  Andreas Pasch; Geoffrey A Block; Matthias Bachtler; Edward R Smith; Wilhelm Jahnen-Dechent; Spyridon Arampatzis; Glenn M Chertow; Patrick Parfrey; Xiaoye Ma; Juergen Floege
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-09       Impact factor: 8.237

6.  Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.

Authors:  Wei Lv; Lina Guan; Yan Zhang; Shengqiang Yu; Bofeng Cao; Yongqiang Ji
Journal:  Int Urol Nephrol       Date:  2016-07-27       Impact factor: 2.370

7.  Associations between coronary calcification on chest radiographs and mortality in hemodialysis patients.

Authors:  Joseph A Abdelmalek; Paul Stark; Carl P Walther; Joachim H Ix; Dena E Rifkin
Journal:  Am J Kidney Dis       Date:  2012-08-09       Impact factor: 8.860

8.  Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis.

Authors:  Maria Fusaro; Marianna Noale; Giovanni Tripepi; Sandro Giannini; Angela D'Angelo; Angelo Pica; Lorenzo A Calò; Davide Miozzo; Maurizio Gallieni
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

9.  Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients.

Authors:  Mengjing Wang; Haiming Li; Li You; Xiaoling Yu; Min Zhang; Ruijiang Zhu; Chuanming Hao; Zhijie Zhang; Jing Chen
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

Review 10.  Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.

Authors:  Megan M Weivoda; Merry Jo Oursler
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.